Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors

Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKI) are a therapeutic option as second-line therapy in non-small-cell lung carcinoma (NSCLC), regardless of the EGFR gene status. Identifying patients with early progression during EGFR-TKI treatment will help clinicians to choose th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rozensztajn, Nathalie, Ruppert, Anne-Marie, Lavole, Armelle, Leprieur, Etienne Giroux, Duruisseaux, Michael, Vieira, Thibault, Rabbe, Nathalie, Lacave, Roger, Antoine, Martine, Cadranel, Jacques, Wislez, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Ltd. 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930390/
https://www.ncbi.nlm.nih.gov/pubmed/24408092
http://dx.doi.org/10.1002/cam4.180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930390/
https://www.ncbi.nlm.nih.gov/pubmed/24408092
http://dx.doi.org/10.1002/cam4.180

Ejemplares similares